Equities analysts expect that Exelixis, Inc. (NASDAQ:EXEL) will announce earnings per share (EPS) of $0.20 for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Exelixis’ earnings, with estimates ranging from $0.16 to $0.22. Exelixis posted earnings of $0.41 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 51.2%. The firm is expected to report its next earnings report on Thursday, November 7th.
According to Zacks, analysts expect that Exelixis will report full year earnings of $0.93 per share for the current fiscal year, with EPS estimates ranging from $0.80 to $0.99. For the next year, analysts anticipate that the firm will post earnings of $1.06 per share, with EPS estimates ranging from $0.82 to $1.15. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Exelixis.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.02. Exelixis had a net margin of 70.52% and a return on equity of 31.31%. The firm had revenue of $240.28 million for the quarter, compared to the consensus estimate of $226.97 million. During the same quarter in the prior year, the company posted $0.31 earnings per share. The business’s revenue was up 29.1% on a year-over-year basis.
EXEL traded up $0.19 during trading on Wednesday, hitting $16.98. 59,625 shares of the company’s stock were exchanged, compared to its average volume of 2,539,121. The company has a quick ratio of 8.53, a current ratio of 8.64 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $18.54 and its two-hundred day moving average is $20.39. Exelixis has a fifty-two week low of $13.42 and a fifty-two week high of $25.31. The stock has a market cap of $5.00 billion, a P/E ratio of 11.84 and a beta of 1.81.
In other news, insider Michael Morrissey sold 35,040 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $20.25, for a total value of $709,560.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George A. Scangos sold 40,000 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $20.59, for a total transaction of $823,600.00. Following the completion of the sale, the director now owns 1,134,081 shares of the company’s stock, valued at approximately $23,350,727.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 350,974 shares of company stock valued at $7,005,921. 4.50% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in EXEL. U S Global Investors Inc. grew its position in Exelixis by 139.1% during the second quarter. U S Global Investors Inc. now owns 53,359 shares of the biotechnology company’s stock valued at $1,140,000 after buying an additional 31,047 shares during the period. Janus Henderson Group PLC raised its stake in shares of Exelixis by 390.8% during the second quarter. Janus Henderson Group PLC now owns 159,966 shares of the biotechnology company’s stock worth $3,418,000 after acquiring an additional 127,372 shares in the last quarter. First Mercantile Trust Co. raised its stake in shares of Exelixis by 10.9% during the second quarter. First Mercantile Trust Co. now owns 6,386 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 627 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Exelixis by 8.0% during the second quarter. First Trust Advisors LP now owns 5,865,637 shares of the biotechnology company’s stock worth $125,349,000 after acquiring an additional 433,202 shares in the last quarter. Finally, Man Group plc raised its stake in shares of Exelixis by 194.8% during the second quarter. Man Group plc now owns 156,599 shares of the biotechnology company’s stock worth $3,346,000 after acquiring an additional 103,477 shares in the last quarter. Institutional investors own 77.41% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: G-20
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.